PMID- 29693023
OWN - NLM
STAT- MEDLINE
DCOM- 20180830
LR  - 20231112
IS  - 2314-7156 (Electronic)
IS  - 2314-8861 (Print)
IS  - 2314-7156 (Linking)
VI  - 2018
DP  - 2018
TI  - Kidney Transplantation: The Challenge of Human Leukocyte Antigen and Its 
      Therapeutic Strategies.
PG  - 5986740
LID - 10.1155/2018/5986740 [doi]
LID - 5986740
AB  - Kidney transplantation remains the treatment of choice for end-stage renal 
      failure. When the immune system of the recipient recognizes the transplanted 
      kidney as a foreign object, graft rejection occurs. As part of the host immune 
      defense mechanism, human leukocyte antigen (HLA) is a major challenge for graft 
      rejection in transplantation therapy. The impact of HLA mismatches between the 
      donor and the potential recipient prolongs the time for renal transplantation 
      therapy, tethered to dialysis, latter reduces graft survival, and increases 
      mortality. The formation of pretransplant alloantibodies against HLA class I and 
      II molecules can be sensitized through exposures to blood transfusions, prior 
      transplants, and pregnancy. These preformed HLA antibodies are associated with 
      rejection in kidney transplantation. On the other hand, the development of de 
      novo antibodies may increase the risk for acute and chronic rejections. Allograft 
      rejection results from a complex interplay involving both the innate and the 
      adaptive immune systems. Thus, further insights into the mechanisms of tissue 
      rejection and the risk of HLA sensitization is crucial in developing new 
      therapies that may blunt the immune system against transplanted organs. 
      Therefore, the purpose of this review is to highlight facts about HLA and its 
      sensitization, various mechanisms of allograft rejection, the current 
      immunosuppressive approaches, and the directions for future therapy.
FAU - Alelign, Tilahun
AU  - Alelign T
AUID- ORCID: 0000-0001-8384-2593
AD  - College of Natural Sciences, Department of Microbial, Cellular and Molecular 
      Biology, Addis Ababa University, P.O. Box 1176, Addis Ababa, Ethiopia.
AD  - Department of Biology, Debre Berhan University, P.O. Box 445, Debre Berhan, 
      Ethiopia.
AD  - Armauer Hansen Research Institute, Addis Ababa, Ethiopia.
FAU - Ahmed, Momina M
AU  - Ahmed MM
AD  - St. Paul's Hospital Millennium Medical College and Addis Ababa University, Addis 
      Ababa, Ethiopia.
FAU - Bobosha, Kidist
AU  - Bobosha K
AD  - Armauer Hansen Research Institute, Addis Ababa, Ethiopia.
FAU - Tadesse, Yewondwossen
AU  - Tadesse Y
AD  - School of Medicine, College of Health Sciences, Addis Ababa University, Addis 
      Ababa, Ethiopia.
FAU - Howe, Rawleigh
AU  - Howe R
AD  - Armauer Hansen Research Institute, Addis Ababa, Ethiopia.
FAU - Petros, Beyene
AU  - Petros B
AD  - College of Natural Sciences, Department of Microbial, Cellular and Molecular 
      Biology, Addis Ababa University, P.O. Box 1176, Addis Ababa, Ethiopia.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20180305
PL  - Egypt
TA  - J Immunol Res
JT  - Journal of immunology research
JID - 101627166
RN  - 0 (HLA Antigens)
RN  - 0 (Isoantibodies)
RN  - 0 (Isoantigens)
SB  - IM
MH  - Adaptive Immunity
MH  - Animals
MH  - Graft Rejection/*immunology
MH  - HLA Antigens/*immunology
MH  - Histocompatibility
MH  - Humans
MH  - Immunity, Innate
MH  - Immunization
MH  - Immunosuppression Therapy
MH  - Isoantibodies/metabolism
MH  - Isoantigens/immunology
MH  - *Kidney Transplantation
MH  - Transplantation Immunology
PMC - PMC5859822
EDAT- 2018/04/26 06:00
MHDA- 2018/08/31 06:00
PMCR- 2018/03/05
CRDT- 2018/04/26 06:00
PHST- 2017/09/01 00:00 [received]
PHST- 2017/11/30 00:00 [revised]
PHST- 2017/12/03 00:00 [accepted]
PHST- 2018/04/26 06:00 [entrez]
PHST- 2018/04/26 06:00 [pubmed]
PHST- 2018/08/31 06:00 [medline]
PHST- 2018/03/05 00:00 [pmc-release]
AID - 10.1155/2018/5986740 [doi]
PST - epublish
SO  - J Immunol Res. 2018 Mar 5;2018:5986740. doi: 10.1155/2018/5986740. eCollection 
      2018.